Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease

Journal of Clinical Oncology

Volumn 32, Issue 27, 2014, Pages 3012-3020

  Roberts, Kathryn G ^a   Pei, Deqing ^a   Campana, Dario ^a   Payne Turner, Debbie ^a   Li, Yongjin ^a   Cheng, Cheng ^a   Sandlund, John T ^a,b   Jeha, Sima ^a,b   Easton, John ^a   Becksfort, Jared ^a   Zhang, Jinghui ^a   Coustan Smith, Elaine ^a   Raimondi, Susana C ^a   Leung, Wing H ^a,b   Relling, Mary V ^a,b   Evans, William E ^a,b   Downing, James R ^a   Mullighan, Charles G ^a   Pui, Ching Hon ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BCR ABL1 PROTEIN; CD135 ANTIGEN; JANUS KINASE 1; JANUS KINASE 2; MERCAPTOPURINE; METHOTREXATE; MIXED LINEAGE LEUKEMIA PROTEIN; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RAS PROTEIN; TRANSCRIPTION FACTOR 7 LIKE 1; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN;

ABL1 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CHILD; CLINICAL ARTICLE; CRLF2 GENE; CSF1R GENE; DOWN SYNDROME; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NUP214 GENE; ONCOGENE; ONCOGENE N RAS; OVERALL SURVIVAL; P2RY8 GENE; RISK DIRECTED THERAPY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SSBP2 GENE; TREATMENT OUTCOME; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENETICS; INFANT; KAPLAN MEIER METHOD; MOLECULARLY TARGETED THERAPY; NEOPLASM, RESIDUAL; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SALVAGE THERAPY;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION PROFILING; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK ASSESSMENT; RISK FACTORS; SALVAGE THERAPY;

EID: 84907187094     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.4105     Document Type: Article

References (38)

1. Mullighan CG, Su X, Zhang J., et al.: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470-480, 2009
2. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al.: A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study. Lancet Oncol 10:125-134, 2009
3. Roberts KG, Morin RD, Zhang J, et al.: Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22:153-166, 2012
4. Russell LJ, Capasso M, Vater I., et al.: Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 114:2688-2698, 2009
5. Mullighan CG, Collins-Underwood JR, Phillips L.A., et al.: Rearrangement of CRLF2 in B-progenitor-and Down syndrome-associated acute lymphoblas-tic leukemia. Nat Genet 41:1243-1246, 2009
6. Mullighan CG, Zhang J, Harvey R.C., et al.: JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 106:9414-9418, 2009
7. Roberts KG, Li Y, Payne-Turner D, et al.: Genomic characterization and experimental modeling of BCR-ABL1-like acute lymphoblastic leukemia. American Society of Hematology Annual Meeting 122, 2013 (abstr 232)
8. Chen IM, Harvey RC, Mullighan C.G., et al.: Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lympho-blastic leukemia: A Children's Oncology Group study. Blood 119:3512-3522, 2012
9. van der Veer A, Waanders E, Pieters R, et al.: Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 122:2622-2629, 2013
10. Loh ML, Zhang J, Harvey R.C., et al.: Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group TARGET Project. Blood 121:485-488, 2013
11. Kiyokawa N, Iijima K, Yoshihara H., et al.: An analysis of Ph-like ALL in Japanese patients. American Society of Hematology Annual Meeting 122, 2013 (abstr 352)
12. Te Kronnie G, Silvestri D, Vendramini E., et al.: Philadelphia-like signature in childhood acute lymphoblas-tic leukemia: The AEIOP experience. American Society of Hematology Annual Meeting 122, 2013 (abstr 353)
13. Roberts KG, Payne-Turner D, Pei D., et al.: Integrated genomic and mutational profiling of adolescent and young adult all identifies a high frequency of BCR-ABL1-like ALL cases with very poor outcome. American Society of Hematology Annual Meeting 122, 2013 (abstr 825)
14. Pui CH, Campana D, Pei D., et al.: Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360:2730-2741, 2009
15. Pui CH, Evans WE: Acute lymphoblastic leukemia. N Engl J Med 339:605-615, 1998
16. Coustan-Smith E, Sancho J, Hancock M.L., et al.: Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96:2691-2696, 2000
17. Neale GA, Coustan-Smith E, Stow P., et al.: Comparative analysis of flow cytometry and poly-merase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 18:934-938, 2004
18. Pounds S, Cheng C, Mullighan C., et al.: Reference alignment of SNP microarray signals for copy number analysis of tumors. Bioinformatics 25:315-321, 2009
19. Venkatraman ES, Olshen AB: A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23:657-663, 2007
20. Mullighan CG, Goorha S, Radtke I., et al.: Genome-wide analysis of genetic alterations in acute lymphoblas-tic leukaemia. Nature 446:758-764, 2007
21. Tibshirani R, Hastie T, Narasimhan B., et al.: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 99:6567-6572, 2002
22. Zhang J, Mullighan CG, Harvey R.C., et al.: Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 118:3080-3087, 2011
23. Zhang J, Ding L, Holmfeldt L., et al.: The genetic basis of early T-cell precursor acute lympho-blastic leukaemia. Nature 481:157-163, 2012
24. Holmfeldt L, Wei L, Diaz-Flores E, et al.: The genomic landscape of hypodiploid acute lympho-blastic leukemia. Nat Genet 45:242-252, 2013
25. Shah S, Schrader KA, Waanders E, et al.: A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet 45:1226-1231, 2013
26. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 2002
27. Harvey RC, Mullighan CG, Wang X, et al.: Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: Correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 116:4874-4884, 2010
28. Harvey RC, Mullighan CG, Chen I.M., et al.: Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lympho-blastic leukemia. Blood 115:5312-5321, 2010
29. Perez-Andreu V, Roberts KG, Harvey R.C., et al.: Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet 45:1494-1498, 2013
30. Tasian SK, Doral MY, Borowitz M.J., et al.: Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lympho-blastic leukemia. Blood 120:833-842, 2012
31. Maude SL, Tasian SK, Vincent T, et al.: Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 120:3510-3518, 2012
32. Weston BW, Hayden MA, Roberts K.G., et al.: Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol 31:e413-e416, 2013
33. Lengline E, Beldjord K, Dombret H., et al.: Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica 98:e146-e148, 2013
34. Inokuchi K, Wakita S, Hirakawa T., et al.: RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations. Int J He-matol 94:255-260, 2011
35. Schultz KR, Bowman WP, Aledo A, et al.: Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: A Children's Oncology Group study. J Clin Oncol 27:5175-5181, 2009
36. Biondi A, Schrappe M, De Lorenzo P, et al.: Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study. Lancet Oncol 13:936-945, 2012
37. Moorman AV: The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev 26:123-135, 2012
38. Pui CH, Evans WE: A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol 50:185-196, 2013